Lamellipodin promotes invasive 3D cancer cell migration via regulated interactions with Ena/VASP and SCAR/WAVE by Carmona, G et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1038/onc.2016.47
Document Version
Publisher's PDF, also known as Version of record
Link to publication record in King's Research Portal
Citation for published version (APA):
Carmona, G., Perera, U., Gillett, C., Naba, A., Law, A-L., P Sharma, V., ... Krause, M. (2016). Lamellipodin
promotes invasive 3D cancer cell migration via regulated interactions with Ena/VASP and SCAR/WAVE.
Oncogene. 10.1038/onc.2016.47
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 18. Feb. 2017
OPEN
ORIGINAL ARTICLE
Lamellipodin promotes invasive 3D cancer cell migration via
regulated interactions with Ena/VASP and SCAR/WAVE
G Carmona1,11, U Perera2,11, C Gillett3, A Naba1, A-L Law2, VP Sharma4,5, J Wang6, J Wyckoff1, M Balsamo1, F Mosis2, M De Piano7,
J Monypenny2,3,8, N Woodman3, RE McConnell1, G Mouneimne9, M Van Hemelrijck7, Y Cao6, J Condeelis4,5, RO Hynes1,10,
FB Gertler1 and M Krause2
Cancer invasion is a hallmark of metastasis. The mesenchymal mode of cancer cell invasion is mediated by elongated membrane
protrusions driven by the assembly of branched F-actin networks. How deregulation of actin regulators promotes cancer cell
invasion is still enigmatic. We report that increased expression and membrane localization of the actin regulator Lamellipodin
correlate with reduced metastasis-free survival and poor prognosis in breast cancer patients. In agreement, we ﬁnd that
Lamellipodin depletion reduced lung metastasis in an orthotopic mouse breast cancer model. Invasive 3D cancer cell migration as
well as invadopodia formation and matrix degradation was impaired upon Lamellipodin depletion. Mechanistically, we show that
Lamellipodin promotes invasive 3D cancer cell migration via both actin-elongating Ena/VASP proteins and the Scar/WAVE complex,
which stimulates actin branching. In contrast, Lamellipodin interaction with Scar/WAVE but not with Ena/VASP is required for
random 2D cell migration. We identiﬁed a phosphorylation-dependent mechanism that regulates selective recruitment of
these effectors to Lamellipodin: Abl-mediated Lamellipodin phosphorylation promotes its association with both Scar/WAVE and
Ena/VASP, whereas Src-dependent phosphorylation enhances binding to Scar/WAVE but not to Ena/VASP. Through these selective,
regulated interactions Lamellipodin mediates directional sensing of epidermal growth factor (EGF) gradients and invasive 3D
migration of breast cancer cells. Our ﬁndings imply that increased Lamellipodin levels enhance Ena/VASP and Scar/WAVE activities
at the plasma membrane to promote 3D invasion and metastasis.
Oncogene advance online publication, 21 March 2016; doi:10.1038/onc.2016.47
INTRODUCTION
Breast cancer metastasis is one of the leading causes of cancer-
associated mortality in women worldwide.1 Metastasis is a multistep
process.2 After breaching, the basement membrane metastasizing
cancer cells migrate through the dense extracellular matrix (ECM) of
the tumor stroma in order to intravasate.2,3 Carcinoma cells that
migrate in a mesenchymal mode form elongated membrane
protrusions driven by the assembly of branched F-actin networks.
Actin polymerization-driven migration and invasion is coordinated
by the proto-oncogenes c-Src and c-Abl kinases and cytoskeletal
regulatory proteins including Rac GTPase, the Scar/WAVE complex
and Ena/VASP proteins.4–7
Ena/VASP proteins (Mena, EVL and VASP) enhance processive
ﬁlament elongation.8–14 Mena is upregulated in breast cancer and
promotes invasion.15,16 We identiﬁed Lamellipodin (Lpd) as a binding
partner of Ena/VASP proteins.5,17,18 Lpd localizes to lamellipodia,
thin membrane protrusions at the leading edge of migrating cells.17
The Lpd-Ena/VASP interaction is positively regulated by Abl kinase-
mediated Lpd phosphorylation, which drives Ena/VASP recruitment
to lamellipodia by Lpd.19
Lpd is required for lamellipodium formation17 and binds directly
to the Scar/WAVE complex.20 Scar/WAVE activates the Arp2/3
complex to nucleate branched actin networks during lamellipodia
formation.4–7 Surprisingly, Lpd-driven random cell migration in 2D
requires Lpd binding to Scar/WAVE, but not to Ena/VASP.20
The mechanisms by which actin regulators coordinate the
interplay between actin-elongation and actin-branching factors to
promote cancer cell invasion remain incompletely understood.
Here, we report that Lamellipodin mediates invasive 3D migration
of cancer cells via selective, regulated interactions with Ena/VASP
and Scar/WAVE. Our ﬁndings point to key roles for increased Lpd
levels in breast cancer invasion and metastasis.
RESULTS
We observed higher Lpd levels in invasive and metastatic basal
cell lines compared with noninvasive, luminal tumor cell lines
(Figure 1a). Therefore, we analyzed publicly available data sets21 to
examine whether Lpd mRNA levels correlated with occurrence of
distant metastases in breast cancer patients. Lpd was overexpressed
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in several types of breast tumors compared with matched healthy
tissue (Supplementary Figure 1A). High levels of Lpd mRNA
correlated with reduced metastasis-free and disease-free survival
of breast cancer patients in three separate cohorts (Figures 1b and c;
Supplementary Figures 1B and C).22–24 In addition, we explored
whether Lpd protein expression levels correlate with clinical
outcome for breast cancer patients by staining a tumor microarray
(TMA)25 generated from 312 patients with invasive breast cancer
with anti-Lpd antibodies. Moderately, but not highly, increased
abundance of Lpd in the cytoplasm (Histoscore 2; Hazard ratio (HR)
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Figure 1. Increased Lpd expression correlates with poor prognosis for breast cancer patients. (a) Western blot analysis of Lpd expression in
human breast cancer cell lines with varying metastatic potential. Loading control: Tubulin. (b) Kaplan–Meier analysis of metastasis-free survival
in the NKI295 data set. Patients were stratiﬁed by expression of Lpd. The P-value was calculated by a log-rank test. (c) Kaplan–Meier analysis
of disease-free survival in the NKI295 data set. Patients were stratiﬁed by expression of Lpd. The P-value was calculated by a log-rank test.
(d) Kaplan–Meier plots of breast cancer-associated mortality of histoscores 1–3 for Lpd intensity at the plasma membrane. Histoscore 2: HR
(95% CI): 2.23 (1.26–3.95). (e) Representative examples of Lpd immunohistochemistry staining for histoscores 1–3 for Lpd staining intensity at
the plasma membrane. Scale bar, 5 μm. See also Supplementary Figures S1 and S2.
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(95% conﬁdence interval (CI)): 1.765 (1.026–3.036); Supplementary
Figures 1D and 2A,B) and at the plasma membrane (Histoscore 2:
HR, (95% CI): 2.231 (1.26–3.949); Figures 1d and e; compared
with respective histoscore 1) was signiﬁcantly associated with
increased risk for breast cancer-associated mortality. Furthermore,
we observed an inverse correlation between Lpd intensity at the
plasma membrane and Her2 expression (Supplementary Figure 1E).
Consistent with Lpd’s predominant role at the plasma membrane
in promoting cell motility and migration,17,19,20 we observed a
signiﬁcant association between highly, but not moderately, increased
Lpd staining intensity at the plasma membrane and reduced disease-
free (Histoscore 3: HR (95% CI): 1.652 (1.24–2.428)) and metastasis-free
survival of breast cancer patients (Histoscore 3: HR (95% CI): 1.515
(1.054–2.178); Figure 1e compared with respective histoscore 1).
To investigate the requirement for Lpd in metastasis, we tested
the effect of reducing Lpd expression in MDA-MB-231-LM2 cells
(further referred to as LM2), a highly metastatic derivative of
MDA-MB-231 breast cancer cells,26 on their ability to metastasize
from an orthotopic mammary tumor to the lungs. We generated
stable LM2 cell lines with two independent Lpd-targeting shRNAs or
a non-targeting control shRNA, all three retroviruses also conferring
the cis-linked marker ZsGreen (Supplementary Figure 2C). Lpd
knockdown and control cells were injected orthotopically into the
mammary fat pad of immunodeﬁcient mice. Primary tumors formed
6 weeks after injection from Lpd-deﬁcient cells were similar in size
to those arising from control LM2 cells, suggesting that the loss
of Lpd did not affect primary tumor growth (Figure 2a). Importantly,
only 3 out of 20 mice bearing Lpd-depleted tumors developed
macroscopic lung metastases, compared with 9 out of 10 control
tumor-bearing mice (Figure 2b). In addition, animals with tumors
generated from Lpd-depleted cells that metastasized displayed
signiﬁcantly reduced numbers of pulmonary ZsGreen-positive
metastases compared with the metastatic burden of animals with
control tumors (Figures 2c and d).
We then explored whether Lpd promotes cancer cell invasion
during metastasis. In ﬁxed samples, tumors generated from control
shRNA LM2 cells prominently invaded the surrounding stroma.
However, tumors from Lpd knockdown cells were markedly less
invasive (Figure 2e). We investigated Lpd function in cancer invasion
in more detail by intravital imaging. Compared with control shRNA
LM2 tumors, Lpd knockdown tumors had fewer motile cells, which
migrated less directionally and extended protrusions less frequently
(Figures 2f–i; Supplementary Video 1), indicating that Lpd is
required for invasive cancer cell phenotypes in vivo.
To examine Lpd-driven breast cancer intravasation and
dissemination, we implanted ﬂuorescently labeled MDA-MB-231
breast cancer cells into the perivitelline cavities of zebraﬁsh
embryos. In this assay, the injected cancer cells intravasate, and
then inﬁltrate the trunk of the ﬁsh.27,28 Overexpression of GFP-Lpd
in MDA-MB-231 cells enhanced the frequency of seeding of these
breast cancer cells compared with GFP-expressing control cells
(Figures 2j and k). We then performed tail vein injections of the
Lpd knockdown and control LM2 cell lines into immunocompro-
mised mice and quantiﬁed lung metastases after 28 days to test
whether Lpd inﬂuenced the later stages of the metastatic cascade.
Lpd depletion did not reduce the number of metastatic foci in the
lungs of the mice compared with controls (Supplementary Figures
2D and E). Taken together, our results reveal that Lpd promotes
local tumor invasion, intravasation and metastasis in vivo, but is
not required for extravasation.
Breast cancer cell migration toward blood vessels is guided
by cues from the tumor microenvironment, such as epidermal
growth factor (EGF).29 We reasoned that the effect of Lpd
depletion on EGF-induced 3D invasion might arise from defects
in lamellipodial dynamics. Depletion of Lpd in MDA-MB-231
breast cancer cells decreased lamellipodia size (Supplementary
Figure 3A), similar to B16-F1 mouse melanoma cells, in which
Lpd depletion also reduces protrusion speed under steady-state
conditions.17 EGF-stimulated MDA-MB-231 Lpd knockdown cells
displayed reduced protrusion persistence and distance, without
affecting protrusion speed (Supplementary Figure 3B). We chose
MTLn3 cells, a mammary adenocarcinoma cancer cell line,
in which protrusion responses to EGF have been extensively
characterized, to examine EGF-elicited protrusion in more detail
as lamellipodial size is least affected by Lpd knockdown in
this cell line (Supplementary Figure 3A). In agreement with our
ﬁndings in MDA-MB-231 cells, in EGF-stimulated MTLn3 cells
reduced Lpd levels signiﬁcantly decreased protrusion persis-
tence and distance (Figures 3a and b) but did not affect
protrusion speed (Supplementary Figure 3D), compared with
controls. Lpd was diffusely distributed throughout the cytoplasm
of serum-starved cells, but was rapidly recruited to the cell edge
following bath application of EGF (Figures 3c and d). Lamellipo-
dial initiation was detected 30 s after EGF stimulation in
Ctrl-shRNA-expressing cells but was delayed signiﬁcantly when
Lpd levels were reduced (Figures 3b, e and f; Supplementary
Figure 3E; Supplementary Video 3). Taken together, our data
suggest that, in breast cancer cells, Lpd depletion reduces
EGF-elicited lamellipodial protrusion formation and persistence,
but not speed.
Membrane extension during lamellipodial protrusion is driven
by actin polymerization.4–6 To determine how Lpd depletion
inﬂuences actin polymerization, we used a G-actin incorporation
assay30 to measure the abundance and distribution of polymer-
ization-competent, free (uncapped) F-actin barbed-ends in
lamellipodia of living cells. Silencing of Lpd signiﬁcantly reduced
free barbed-end formation 1 min after EGF stimulation, relative to
Ctrl-shRNA-expressing cells (Figures 4a and b). Collectively, these
data indicate that Lpd promotes lamellipodial protrusion by
increasing actin polymerization downstream of EGFR activation.
EGF-dependent membrane protrusion in MTLn3 cells requires
Ena/VASP proteins and Arp2/3-mediated dendritic nucleation;16,31
and Lpd binds both Ena/VASP proteins and the Arp2/3 activating
Scar/WAVE complex.17,19,20 Consistent with this, membrane
recruitment of Mena (Figures 4c and d) and Arp2/3 complex to
the protruding edge (Figures 4e and f) was signiﬁcantly reduced in
Lpd-depleted cells after EGF stimulation.
We hypothesized that the requirement for Lpd in EGF-induced
protrusion reﬂects Lpd-mediated initiation of chemotactic responses.
The initial step of chemotaxis is directional sensing.32,33 We used
a micropipette to generate a spatially restricted EGF gradient.
Ctrl-shRNA MTLn3 cells formed new protrusions toward the pipette,
demonstrating their ability to sense the EGF gradient. However,
those of Lpd-reduced cells were random relative to the micropipette
(Figures 4g and h; Supplementary Figures 4A and B; Supplementary
Video 5). Chemotactic indices conﬁrmed the lack of directional bias
in Lpd-deﬁcient MTLn3 protrusions (Figure 4h), highlighting an
essential role for Lpd in the initial steps of chemotaxis toward EGF.
Lpd is concentrated at the edges of lamellipodia that protrude
in response to uniform EGF stimulation. Correlative differential
interference contrast microscopy and immunoﬂuorescence imaging
in live cells revealed enrichment of Lpd at the edges of cells
oriented toward the micropipettes containing EGF (Supplementary
Figure 4C), conﬁrming that Lpd was enriched in membranes
exposed to the highest concentration of the EGF gradient and
supporting a function for Lpd in linking gradient sensing to directed
membrane protrusion.
We hypothesized that EGF chemosensing might involve Lpd-
mediated recruitment of Ena/VASP proteins. We tested whether
Lpd-depleted cells, expressing either a GFP-Lpd or an Lpd
mutant in which all Ena/VASP binding sites had been rendered
non-functional by mutation (GFP-LpdEVmut), could respond to EGF
gradients in the micropipette assay and discovered that, while
GFP-Lpd effectively rescued the chemosensing defects in Lpd-
depleted cells, GFP-LpdEVmut conferred no signiﬁcant phenotypic
rescue (Figure 4i and Supplementary Figure 5C). In line with this
Lamellipodin promotes breast cancer metastasis
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ﬁnding, a function-perturbing approach34 revealed that Ena/
VASP proteins were required for chemosensing (Supplementary
Figures 5A and B). Thus, extension of lamellipodia toward
EGF during chemosensing by breast carcinoma cells requires
the Lpd-dependent recruitment of Ena/VASP proteins, despite
the dispensability of Ena/VASP for Lpd-driven random 2D cell
migration.
We next analyzed the requirements for Lpd during EGF-
dependent 3D invasion. In 3D inverted chemotaxis assays toward
EGF with MDA-MB-231 or SUM-159 invasive breast cancer
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lines35,36 knockdown of Lpd signiﬁcantly decreased invasion
through matrigel (Figures 5a and b; Supplementary Figure 6A)
and collagen (Supplementary Figures 6B–D) compared with
control shRNA expressing cells. Conversely, Lpd overexpression
signiﬁcantly increased invasion toward EGF (Figures 5d and e).
As invasion is known to be partially dependent on matrix
metalloproteinase (MMP) digestion of ECM, we tested whether Lpd
increases invasion via MMP-dependent or migration-dependent
mechanisms. MMP inhibitor treatment of GFP-expressing control
cells reduced invasion, as expected. Similarly, MMP inhibitor
treatment reduced invasion of Lpd overexpressing MDA-MB-231
cells. However, Lpd overexpressing cells treated with MMP inhibitors
invaded signiﬁcantly further compared with GFP control cells
treated with the inhibitor, suggesting that Lpd functions to increase
invasion by increasing migration and potentially MMP-dependent
ECM degradation (Figure 5c and Supplementary Figure 6E).
The aforementioned ﬁndings prompted us to investigate Lpd’s
role in MMP-dependent degradation. Carcinoma cells can utilize
protrusive invadopodia, sites of MMP exocytosis, to invade through
the basement membrane and ECM-rich interstitial stroma.37–39 We
observed that Lpd co-localized with the invadopodial marker
cortactin at invadopodia, at sites of matrix degradation (Figure 5f).
Previously, we reported that Mena promotes invadopodium
stabilization and matrix degradation,16 and here we observed that
Lpd depletion appeared to reduce the amount of Mena within
invadopodia considerably, potentially reﬂecting a role for Lpd in
Mena recruitment to invadopodia (Supplementary Figure 6H).
Silencing of Lpd in MDA-MB-231 cells decreased the number
of precursors, mature invadopodia and the total number of
invadopodia in comparison with control cells (Figures 5i and j).
Furthermore, Lpd-depleted MDA-MB-231 cells exhibited a signiﬁ-
cant decrease in their ability to degrade matrix relative to control
cells (Figures 5g and h). Taken together, these results suggest that
Lpd is required for invadopodial precursor formation or for both
precursor formation and subsequent stabilization/maturation, and
for invadopodia-mediated matrix degradation.
To test the relative contribution of Lpd interactions with Ena/VASP
proteins or with the Scar/WAVE complex during MDA-MB-231 3D
invasion, we overexpressed a panel of Lpd mutants in which all
Ena/VASP (GFP-LpdEVmut), all Scar/WAVE-binding sites (GFP-LpdS/Wmut),
or all Ena/VASP and all Scar/WAVE-binding sites (GFP-LpdEV+S/Wmut)
had been mutated. All of these mutants localized to the leading
edge of MDA-MB-231 cells (Supplementary Figures 6F and G).
At steady state when embedded in 3D matrigel, MDA-MB-231 cells
overexpressing GFP-Lpd displayed signiﬁcantly more protrusions,
which protruded faster compared with GFP control cells. However,
expression of Lpd-Ena/VASP-, Lpd-Scar/WAVE- and double-
binding mutants all failed to increase protrusion numbers and
speed (Figure 7h and Supplementary Figure 7G). Similarly, these
mutants did not support invasion through matrigel toward EGF,
suggesting that Lpd promotes 3D chemotactic invasion via both
Ena/VASP and Scar/WAVE (Figures 5d and e). These ﬁndings,
combined with our previous observation that Lpd interaction with
Scar/WAVE but not with Ena/VASP is required for random 2D
migration, prompted us to hypothesize that interactions between
Lpd and these actin regulators may be differentially regulated.
Previously, we found that Lpd is phosphorylated by Abl kinases
upon growth factor stimulation, and this positively regulates its
interaction with Ena/VASP proteins and their recruitment to the
leading edge of cells.19 As Src kinases are also activated upon
growth factor stimulation and increased Src activity promotes
cancer cell invasion,40 we explored whether Lpd interactions with
downstream partners are regulated by Src phosphorylation.
We expressed GFP-Lpd with wild-type c-Src or a kinase-inactive
mutant of c-Src and, after immunoprecipitation of Lpd, observed
that it was tyrosine phosphorylated in cells expressing wild-type but
not kinase-inactive c-Src (Figure 6a). Both Src and Abl kinases are
activated downstream of growth factor receptors, and Src
phosphorylation of Abl kinases contributes to their activation.40–42
To distinguish between Src and Abl phosphorylation of Lpd and to
investigate whether endogenous Lpd is phosphorylated by Src
tyrosine kinases, we made use of Abl/Arg double knockout mouse
embryonic ﬁbroblasts.43 After PDGF-BB stimulation, Lpd was
robustly tyrosine phosphorylated in the absence of both Abl
kinases, Abl and Arg. This was blocked by the Src inhibitor Bosutinib
(Figures 6b and c), indicating that Src kinase activity leads to Lpd
phosphorylation upon growth factor receptor activation.
We ﬁrst investigated whether Src phosphorylation controls Lpd-
Ena/VASP interaction, since this is positively regulated by Abl
phosphorylation.19 Surprisingly, c-Src-induced Lpd phosphoryla-
tion did not affect Lpd-Ena/VASP binding (Supplementary Figures
7A and B). In contrast, co-immunoprecipitation between GFP-Lpd
and Myc-tagged Scar/WAVE complex revealed that signiﬁcantly
more Scar/WAVE complex co-precipitated with Lpd when either
c-Src or c-Abl was co-expressed (Figures 6d–g). We also tested
whether the interaction between endogenous Lpd and Scar/WAVE
is positively regulated by c-Src by using ectopically expressed
GST-tagged Abi (which reduces endogenous Abi and thereby
replaces it44) to efﬁciently pull down the Scar/WAVE complex and
associated proteins. GST-Abi pulldowns from cells co-expressing
GFP-Src contained higher levels of endogenous Scar/WAVE2 co-
precipitating with endogenous Lpd compared with GFP controls
(Supplementary Figures 7C and D). Conversely, GST-Abi pulldowns
from cells co-expressing GFP-Src treated with the c-Src inhibitor
(KB SRC 4) contained lower levels of endogenous Scar/WAVE2
co-precipitating with endogenous Lpd compared with GST-Abi
Figure 2. Lpd is required for lung metastasis from orthotopic mammary tumors. (a–e) NOD/SCID/IL2Rγ-null mice were injected orthotopically
with LM2 cells stably expressing Ctrl-shRNA or Lpd-shRNA1 or Lpd-shRNA2. Tumors were allowed to grow for 6± 0.5 weeks. (a) Primary tumor
weights at the time of killing of individual mice are shown. Data are represented as mean± s.e.m. Number of animals per group is indicated in
(b). (b) The number of mice that presented with visible metastases in the lung is indicated (mice with lung metastases/total number of mice
analyzed). (c) Representative images of whole left pulmonary lobe from LM2 (control or knockdown) tumor-bearing mice with ZsGreen-
positive metastatic foci (top panel). Scale bar, 5 mm. Representative lung sections stained with H&E; arrowhead indicates the presence of
metastatic foci (bottom panel). Scale bar, 20 μm. (d) Numbers of ZsGreen-positive metastatic foci in the left pulmonary lobe were counted.
Quantiﬁcation of data shown in (c, top panel). Data are represented as mean± s.e.m. One-way ANOVA; Dunnett’s; *P⩽ 0.05. Number of animals
per group is indicated in (b). (e) Representative images of parafﬁn tissue sections stained with Masson’s trichrome of primary tumors to show
local invasion. Scale bar, 20 μm. (f–i) Tumor cell motility in vivo monitored by multi-photon confocal imaging. (f) Image shows a Ctrl-shRNA
ZsGreen tumor. Cyan=ZsGreen-positive cells, red= collagen ﬁbers. One motile Ctrl-shRNA-expressing tumor cell is outlined. Scale bar, 40 μm.
(g) The average numbers of motile cells per ﬁeld were determined. Data are represented as mean± s.e.m.. Unpaired t-test; *P⩽ 0.05, n= 5 mice
per group. (h) The average numbers of cells extending protrusions per ﬁeld were determined. Data are represented as mean± s.e.m.; unpaired
t-test; *P⩽ 0.05; n= 5 mice per group. (i) Directionality of the motile cells (net path/total path) was determined. Data are represented as
mean± s.e.m.; unpaired t-test; *P⩽ 0.05; n= 5 mice per group. (j, k) Red ﬂuorescently labeled MDA-MB-231 cells overexpressing GFP-Lpd or
GFP as a control were implanted into the perivitelline cavity of zebraﬁsh embryos and dissemination to the trunk region was quantiﬁed 2 days
after injection. (j) Image of representative zebraﬁsh trunks 2 days after injection. Arrows point to seeded tumor cells. Scale bar, 500 μm.
(k) Quantiﬁed data from (j) represented as mean number of seeded tumor cells per mm of trunk length. Mean± s.e.m; data from 53 ﬁsh
embryos for GFP and from 49 ﬁsh embryos for GFP-Lpd from 3 independent experiments; t-test; **P⩽ 0.01. See also Supplementary Figure S2.
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pulldowns from DMSO-treated control cells (Supplementary
Figures 7E and F). Together, these ﬁndings indicate that the
Lpd-Ena/VASP interaction is regulated by c-Abl phosphorylation,
whereas the Lpd-Scar/WAVE interaction is positively regulated by
both c-Abl and c-Src-dependent phosphorylation.
To better understand this differential regulation, we identiﬁed
potential direct c-Src phosphorylation sites in Lpd, using puriﬁed
c-Src kinase to phosphorylate an immobilized peptide array
covering all putative tyrosine phosphorylation sites in Lpd. This
analysis revealed that Lpd harbors two robustly and four weakly
phosphorylated c-Src tyrosine phosphorylation sites (Figure 7a).
We have previously mapped eight c-Abl tyrosine phosphorylation
sites in Lpd,19 which partly overlap with these newly identiﬁed
c-Src sites (Figure 7a). To verify that the Lpd phosphorylation sites
identiﬁed in vitro were phosphorylated in cells, we mutated the
tyrosines in the six c-Src (GFP-LpdY6F) and the eight c-Abl
phosphorylation sites (GFP-LpdY8F) to phenylalanine, rendering
them non-phosphorylatable. Overexpression of GFP-Lpd induced
low levels of Lpd tyrosine phosphorylation, which was markedly
enhanced by stimulation with 100 ng/ml EGF for 5 min. In contrast,
Fl
uo
re
sc
en
ce
 in
te
ns
ity
at
 th
e 
ce
ll 
ed
ge
 (A
.U
)
40
30
20
10
0
EGF time (Sec)
0 30 60 90 120 150 180
1.00
1.10
1.20
1.30
1.40
M
em
br
an
e 
pr
ot
ru
si
on
(fo
ld 
ch
an
ge
)
0 60 120 180 240 300 360 420
EGF time (Sec)
0s 15s 30s 45s
60s 90s 120s 180s
Ctrl-shRNA
Lpd-shRNA2
Lpd-shRNA3
0.95
1.05
1.15
1.25
1.35
1.45
0s 180s 420s60s
Lpd-shRNA2
Ctrl-shRNA
Pr
ot
ru
si
on
pe
rs
is
te
nc
e 
(S
ec
)
Pr
ot
ru
si
on
 d
is
ta
nc
e
 
(m
)
Time (Sec)
150
100
50
0 0
4
3
2
1
5
Ct
rl-
sh
R
N
A
Lp
d-
sh
R
N
A
2
Ct
rl-
sh
R
N
A
Lp
d-
sh
R
N
A
2
*
*
EGF
D
is
ta
nc
e 
(m
)
Ctrl-shRNA
Lpd-shRNA2
0
50
100
150
*
Pr
ot
ru
si
on
 in
iti
at
io
n 
(ti
me
 in
 se
c)
Lp
d-
sh
R
N
A
2
Ct
rl-
sh
R
N
A
Figure 3. Lpd is required for EGF-induced membrane protrusion. (a) Representative kymographs of Ctrl-shRNA and Lpd-shRNA2 MTLn3 cells. A line
drawn perpendicular to the cell surface is shown for each frame of a time-lapse movie to depict temporal dynamics of cell edge. X axis: time
(arrow length: 20 s); Y axis: distance (arrow length: 3.1 μm). (b) Quantiﬁcation of protrusion parameters from kymographic analysis of Ctrl-shRNA and
Lpd-shRNA2 MTLn3 cells. Data represented as mean± s.e.m. Unpaired t-test; *P⩽0.05. (c) Micrographs showing immunoﬂuorescence for endogenous
Lpd in MTLn3 cells stimulated with 5 nM EGF (post-stimulation time is indicated). Scale bar, 10 μm. (d) Quantiﬁcation of data shown in (c): mean
ﬂuorescence intensity of Lpd within a 0.66-μm zone at the lamellipodial edge is plotted as a function of time;430 cells analyzed from at least three
independent experiments. Error bars indicate s.e.m. (e) Representative micrographs from time-lapse movies of Ctrl-shRNA (control non-targeting
shRNA) and Lpd-shRNA2-expressing MTLn3 cells stimulated with 5 nM EGF. Dashed line shows cell edge. Scale bar, 10 μm. (f) Quantiﬁcation of
membrane protrusions on Ctrl-shRNA and Lpd-shRNA-treated cells. Cell area was determined after EGF stimulation and normalized to the
pretreatment cell area; 430 cells analyzed from three independent experiments. Error bars indicate s.e.m. See also Supplementary Figure S3.
Lamellipodin promotes breast cancer metastasis
G Carmona et al
6
Oncogene (2016) 1 – 15 © 2016 Macmillan Publishers Limited
neither GFP-LpdY6F nor GFP-LpdY8F tyrosine phosphorylation was
enhanced when cells expressing these constructs were stimulated
with EGF (Figures 7b and c). We found that the
GFP-LpdY6F and GFP-LpdY8F mutants interacted signiﬁcantly less
with the Scar/WAVE complex (Figures 7f and g; Supplementary
Figure 8D). Nevertheless, GFP-LpdY6F and -LpdY8F mutants localized
to the leading edge of MDA-MB-231 cells similar to wild-type Lpd
(Supplementary Figures 6F and G). Taken together, our data indicate
that full-length Lpd can be phosphorylated at these sites in cells
upon EGFR activation, likely as a consequence of activated Abl
and Src kinases.
To verify that both Src and Abl kinases are required for breast
cancer invasion toward EGF, we tested the invasiveness of
MDA-MB-231 cells with and without incubation with the Src and
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Abl inhibitors Dasatinib or STI571. As expected, we found that
breast cancer cell invasiveness is impaired when Src or Abl kinases
were inhibited (Supplementary Figures 8A and B).
To investigate the functional signiﬁcance of Lpd tyrosine
phosphorylation for breast cancer invasion, we compared the
effects of overexpressing the non-phosphorylatable mutants,
GFP-LpdY6F or GFP-LpdY8F with control GFP-Lpd. We observed
that, in contrast to GFP-Lpd, neither of the mutants increased
protrusion numbers or speed in cells embedded in matrigel at
steady state, or the invasiveness of breast cancer cells through
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matrigel toward EGF (Figures 7d, e and h and Supplementary
Figure 8C), suggesting that phosphorylation by both Abl and Src
kinases is required for Lpd-mediated breast cancer invasion.
DISCUSSION
Here, we reveal that Lpd is required for metastasis in an
orthotopic breast cancer mouse model, and that increased Lpd
levels correlate with reduced metastasis-free survival in breast
cancer patients. Lpd promotes metastasis in vivo by supporting
tumor invasion and intravasation. Lpd function in metastasis
may be mediated via both Ena/VASP and the Scar/WAVE
complex since we observed that Lpd mediates breast cancer
invasion via both actin effectors. Both Ena/VASP and Scar/WAVE
are implicated in breast cancer metastasis by multiple lines of
evidence.15,16,45,46 Our results suggest that the pro-metastatic
function of Lpd may, in part, involve coordinating the activities
of these two distinct types of actin regulators to optimize
chemotactic invasion and matrix degradation by invading
tumor cells.
Here, we provide evidence that Lpd is a substrate of Src kinases
and that phosphorylation of Lpd by Src positively regulates the
Lpd-Scar/WAVE complex interaction, but not the Lpd-Ena/VASP
interaction, whereas c-Abl-mediated phosphorylation of Lpd
positively regulates both Lpd-Ena/VASP and Lpd-Scar/WAVE
interaction. This differential regulation of Lpd-Ena/VASP or Lpd-
Scar/WAVE recruitment may allow Lpd to ﬁne-tune actin
cytoskeletal dynamics via Ena/VASP-mediated actin ﬁlament
elongation and Scar/WAVE-Arp2/3-mediated nucleation/branch-
ing, consistent with the context-dependent differential require-
ments for these interactions we observed. Lpd-driven random 2D
cell migration requires Scar/WAVE, but not Ena/VASP,20
Lpd-dependent chemosensing in 2D requires Ena/VASP, and
interactions with both SCAR/WAVE and Ena/VASP are required for
3D chemotaxis and migration. These ﬁndings lead to the
interesting possibility that Lpd balances actin nucleation/branch-
ing and ﬁlament elongation activities to optimize protrusion
morphology and dynamics during cellular responses to growth
factors and ECM composition and organization.
Surprisingly, we observed that only moderately, but not highly
increased levels of Lpd correlate with increased risk of breast
cancer-associated mortality, suggesting that not all of Lpd functions
(cell invasion, cell proliferation and EGFR endocytosis)47,48 induced
by high but not medium levels of Lpd may be beneﬁcial for tumors
cells. However, in agreement with its role in metastasis, we found
that highly increased Lpd abundance at the plasma membrane of
cancer cells in breast tumors correlates with reduced disease- and
metastasis-free interval. The increased membrane accumulation
of Lpd protein observed in our TMA analysis may reﬂect the known
role of Lpd in regulating membrane protrusion in migrating
cells.17,20 Furthermore, consistent with the TMA analysis, we found
that increased Lpd mRNA levels correlate with reduced metastasis-
free survival of breast cancer patients.
On the basis of our ﬁndings, we propose that Lpd functions
as an essential component of a pro-metastatic signaling pathway
composed of Src and Abl kinases, Lpd, Ena/VASP and Scar/WAVE
that promotes metastatic progression.
MATERIALS AND METHODS
Plasmids and shRNAs
GFP-VASP, pMSCV-mRFP1-FP4/AP4-mito,34 Myc-Pir121, -Nap1, -Abi1d,
-WAVE2 in pRK5-Myc-DEST20 and Lpd17 in pENTR (Invitrogen) mutated
using Quikchange (Agilent), transferred into pCAG-DEST-EGFP (Gateway)
(pCAG-EGFP; C Cepko, Addgene,11150) and pCB6-Src-WT-EGFP, pCB6-Src-
KI (kinase-inactive)-EGFP49 (M Way).
GFP-LpdS/Wmut: 20(AAS82582.1) Site 1: (aa 968–978) GKKP(P4A) (P4A) T
(P4A)Q(R4A)N; Site 2: (aa 1119–1129) APP(P4A)TR(P4A)K(R4A)ND;
Site 3: (aa 1230–1244) RRGP(P4A)A(P4A)(P4A)(K4A)(R4A)DQNT.
GFP-LpdEVmut: 20(AAS82582.1) FP4-1: aa 869 F4A; FP4-2: aa 916 F4A;
FP4-3: aa927 F4A; FP4-4: aa 1064 F4A; FP4-5: aa1073 F4A; FP4-6: aa1082
L4A; FP4-7: aa1202 L4A.
GFP-LpdY4F: 19(AAS82582.1) Y4F: aa 426, 456, 513, 1226; GFP-LpdY6F:
(AAS82582.1) Y4F: aa 366, 426, 456, 466, 481, 510; GFP-LpdY8F:
(AAS82582.1) Y4F: aa 366, 426, 456, 466, 481, 510, 513, 1226.
pLJM1-H2BK-mCherry: histone H2BK ampliﬁed from A431 cell by RT–PCR
cloned into pLJM1-mCherry (D Sabatini; Addgene plasmid #19319).
shRNAs were cloned into pLL3.7-Puro, miR30-MLS EGFP/mCherry50 or
MSCV-ZsG-2A-Puro-miR30 retroviral vector.51 Cells were FACS sorted or
puromycin (Invitrogen) selected and knockdown tested by western
blotting. shRNA (5′–3′) used:
Human Lpd-shRNA1: TTTCCCCAAAAGATAATTCTG, humanLpd-shRNA2: TTCC
CATACTTTGCAATGCGG, ratLpd-shRNA2: TAGAGCTCACAGTACTTTGGG, ratLpd-
shRNA3: AAGAGGTCCAATCATAAGCTG and Control-shRNA (targeting luciferase):
TTAATTAAAGACTTCAAGCGG (Figures 2–4 and Supplementary Figures S2–S6).
Human Lpd-shRNA-1:GCGTCAAATCACAGAAACG, Human Lpd-shRNA-2:GCTCTG
AATCAGGGAGAGA and Control-shRNA (Lpd-scrambled): GCCGATAACCGAGAA
TACC (Figures 2 and 5; Supplementary Figures S2 and S6).
Cell culture and transfection
HEK293, BT549, MCF7 and T47D cells obtained from ATCC and
maintained according to ATCC’s protocol. SUM-159 and MTLn3
cells cultured as described.52,53 HEK cells expressing GST-Abi2 and
GFP-Src were treated for 1 h with 100 μM KB SRC 4 (Tocris) before lysis.
Figure 5. Lpd is required for 3D invasion of cancer cells. (a, b) Inverted invasion assays were performed using MDA-MB-231 cells stably
expressing mCherry-H2B (labeling the nucleus) transfected with Ctrl-shRNA, Lpd-shRNA1 or Lpd-shRNA2. Additionally, cells were co-
transfected with empty Blasticidin vector as well and transfected cells were selected. The nuclei of the cells were visualized using confocal
microscopy. (a) The image stacks were processed by Volocity software to make a 3D reconstruction. (b) Quantiﬁcation of the number of nuclei
of invading cells above 40 μm from the data shown in (a), n= 4 (with approximately 4000 cells per experiment). Data are represented as
mean± s.e.m. One-way ANOVA; Dunnett's; *P⩽ 0.05. (c) Inverted invasion assays with GFP or GFP-Lpd expressing MDA-MB-231 cells treated
with the MMP inhibitor 10 μM GM6001 or just the solvent DMSO as a control. Quantiﬁcation of the number of nuclei of invading cells above
40 μm from the data shown in Supplementary Figure 6E. n= 3. Data are represented as mean± s.e.m. One-way ANOVA; Tukey’s; *P⩽ 0.05,
**P⩽ 0.01, ***P⩽ 0.001. (d) Inverted invasion assays were performed using MDA-MB-231 breast cancer cells stably expressing mCherry-H2B
(labeling the nucleus) transfected with GFP-Lpd, GFP-LpdEVmut, GFP-LpdS/Wmut, GFP-LpdEV+S/Wmut or GFP empty vector as a control. The nuclei
of the cells were visualized using confocal microscopy. The image stacks were processed by Volocity software to make a 3D reconstruction.
(e) Quantiﬁcation of the number of nuclei of invading cells above 40 μm from the data shown in (d), n= 3 (with approximately 4000 cells per
experiment). Data are represented as mean± s.e.m. One-way ANOVA; Dunnett's; *P⩽ 0.05, **P⩽ 0.01, ***P⩽ 0.001. (f) MDA-MB-231 plated on
Alexa 488-gelatin/ﬁbronectin matrix, ﬁxed and stained for Lpd, and the invadopodia marker cortactin. White boxes: enlarged images shown in
insets. Scale bar: 10 μm. (g) Steady-state assay for invadopodial matrix degradation. MDA-MB-231 cells were plated for 8 h on Alexa
488-gelatin/ﬁbronectin matrices, ﬁxed and stained with phalloidin. Scale bar, 10 μm. (h) Quantiﬁcation of data shown in (g): invadopodial
degradation area/cells in the steady-state matrix degradation assay, normalized to number of cells/ﬁeld. Data are represented as mean± s.e.m.
(n= 3). Mann–Whitney test; *Po0.05. (i) MDA-MB-231 stably expressing Ctrl-shRNA or Lpd-shRNA cells were plated on 405-gelatin and
immunostained with cortactin and Tks5 antibodies to identify invadopodia. Scale bar, 10 μm. (j) Quantiﬁcation of data shown in (i); number of
total invadopodia, invadopodia precursors and mature invadopodia per cell were determined; Ctrl-shRNA cells (n= 52) or Lpd-shRNA cells
(n= 57). Data are represented as mean± s.e.m. Mann–Whitney test; *Po0.05. See also Supplementary Figure S6.
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Abl1/Abl2 double knockout MEFs (gift of T Koleske, Yale), MDA-MB-231
cells (gift of A Ridley) and MDA-MB-231 LM2 cells26 (gift from J
Massague, MSKCC) were cultured in high-glucose DMEM, penicillin,
streptomycin, 10% FBS. MTLn3 and MDA-MB-231 transfection was done
using Lipofectamine 2000 (Invitrogen). Abl1/2DKO MEFs were serum
starved (18 h) and treated with 10 μM Bosutinib (Cambridge Biosciences)
(2 h) in DMSO or DMSO (control), then stimulated with 20 ng/ml PDGF-
BB (2 min).
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Antibodies
Lpd pab 3917,17 Mena mab A351F7D9,54 Wave2 (Cell Signaling Technol-
ogy), p34Arc (Millipore, 07-227), Tubulin (DM1A), Hsc70 mab (Santa Cruz),
GFP mab (Roche), Myc mab (Sigma, 9E10), pTyr mab (Millipore, 4G10) and
Vimentin (550513, Biosciences). Alexa-conjugated secondary antibodies,
phalloidin (Invitrogen, Biotium) diluted 1:50–1000.
Immunoprecipitation, GST-pulldowns and western blotting
Immunoprecipitation, GST-pulldowns and western blotting were per-
formed as described.20
Peptide array assay
Peptide array assay was done using Src kinase (NEB) as described.19
Immunoﬂuorescence microscopy
Cells were plated on glass coverslips, ﬁxed and stained as described.19
Imaged using Deltavision microscope (Applied Precision, Olympus IX71,
× 60/1.4NA, Softworx software) (SGI, Mountain View, CA, USA). Olympus
IX-81 microscope (Metamorph, Photometrics CascadeII 512B camera, × 40
UPlanFL, × 60 PlanApoNA1.45 or × 100 UPlanApoS NA1.4 objectives) was
used. Leading edge localization (Supplementary Figure 6G) was quantiﬁed
by two blinded observers from independent data sets (n=32–38 cells for
each mutant).
Inverted invasion assay
In all, 5 × 105 MDA-MB-231 cells stably expressing mCherry-H2B were
seeded onto underside of 8 μm pore-size transwell inserts (Greiner Bio-One
Ltd) containing matrigel (BD Biosciences, UK; polymerized 30 min (37 °C)).
Inserts were inverted after cells adhered (4 h), placed in serum-free
medium, and normal growth medium containing EGF (25 ng/ml) placed on
top. Inhibitors used were GM6001 μM; STI571 10 μM and Dasatinib 10 nM.
Seventy-two hours later, cells that did not cross the transwell ﬁlter were
removed; invading cells visualized by confocal microscopy; 2.5 μm
sections. The number of nuclei of invading cells above 40 or 80 μm was
automatically quantiﬁed using the Volocity software.
Membrane protrusion assays
Membrane protrusion assay for EGF-treated cells was performed as
described.16 Kymographic analysis was performed to analyze the protru-
sion parameters including: protrusion persistence, distance, velocity and
protrusion initiation after EGF stimulation.
For membrane protrusion assay in 3D matrigel, MDA-MB-231 cells were
stained with CellTracker Green dye (ThermoFisher, UK) embedded in
matrigel (BD Biosciences) in μ-slide chambers (81506; Ibidi, Germany).
Four hours after plating, 5 min movies, one frame every 15 s; × 40;
Olympus IX-81 were generated and protrusive activity around the entire
circumference between frames automatically quantiﬁed from thresholded
movies using ImageJ plugin ADAPT.55
Micropipette assay
The micropipette assay was performed as described.53,56
Barbed-end assay
G-actin was extracted from rabbit muscle acetone powder and standard
techniques used to gel-ﬁlter over a Superdex-200 gel ﬁltration column. The
G-actin was polymerized to F-actin in F-actin buffer (1 mM ATP, 5 mM
MgCl2, 50 mM KCl, 50 mM Tris/HCl, pH 8.0), labeled with Rhodamine-X
succinimidyl ester (Invitrogen; following manufacturer’s instructions),
depolymerized in G-actin buffer (0.2 mM ATP, 0.5 mM DTT, 0.2 mM CaCl2,
2 mM Tris/HCl, pH 8.0) to G-actin, and passed through PD-10 columns
(GE Healthcare) to eliminate free rhodamine. The barbed-end assay in
MTLn3 cells was performed as described.16 Images taken with deconvolu-
tion microscope; the ratio of the barbed-end intensity to phalloidin
intensity along the edge (the zone between 0 and 0.66 μm inside the cell)
quantiﬁed as described above.
Invadopodium degradation and immunoﬂuorescence
MDA-MB-231 cells used in this study were cultured on FN/gelatin matrix
(for 8 h) or thin gelatin matrix (for 4 h), and treated as described.57
Zebraﬁsh tumor cell dissemination assay
The zebraﬁsh tumor cell dissemination assay was done as described.28
Mouse models
Tumor growth and spontaneous metastasis formation assayed by injecting
tumor cells orthotopically into inguinal mammary fat pads (6- to 8-week-
old female NOD/SCID/IL2Rγ-null mice) (Jackson Laboratory, Bar Harbor, ME,
USA). Mice anesthetized with isoﬂurane, injected with 1.5 × 105 cells in
Hank’s Balanced Salt Solution (Gibco); killed 6 ± 0.5 weeks post injection;
tumors dissected, weighed, ﬂash frozen, stored (−80 °C) or ﬁxed: 3.8%
formaldehyde, imaged with a ﬂuorescence microscope, and embedded in
parafﬁn and sectioned. Lungs were collected, ﬁxed: 3.8% formaldehyde,
embedded in parafﬁn, sectioned and stained with hematoxylin and eosin
(H&E). ZsGreen-positive foci were counted in left pulmonary lobe using
ImageJ.
Intravital imaging
Female NOD/SCID/IL2Rγ-null mice (6–8 weeks old) injected in the mammary
fat pad with Ctrl-shRNA or LpdhsRNA2-expressing LM2 cells. Experiments
were performed as described previously.58 Five mice per group were used.
Collagen I ﬁbers were imaged by second harmonic generated polarized light.
Cell motility observed by time-lapse imaging: 30 min in 2-min cycles. Three-
dimensional time-lapse videos were analyzed using Image J. Tumor cell
Figure 6. c-Src phosphorylates Lpd and the Lpd-Scar/WAVE interaction is positively regulated by c-Abl and c-Src. (a) HEK293FT cells were
transfected with either GFP as a control or GFP-Lpd and co-transfected with Src-WT (wild type) or Src-KI (kinase inactive). Immunoprecipitation
was performed from cell lysates using Lpd-speciﬁc antibodies or rabbit IgG as a control followed by western blotting with anti-Lpd and anti-
phosphotyrosine (pTyr) antibodies. n= 3. (b) Abl and Arg double knockout MEFs (Abl/Arg DKO) were serum starved overnight and treated
with 10 μM Bosutinib (c-Src kinase inhibitor) for 2 h before stimulating with 20 ng/ml PDGF-BB for 2 min. Immunoprecipitation was performed
from cell lysates using Lpd-speciﬁc antibodies or rabbit IgG as a control followed by western blotting with anti-Lpd and anti-phosphotyrosine
(pTyr) antibodies. (c) Quantiﬁed band intensities of chemiluminescence blots from (b) of Lpd and pTyr imaged with a CCD camera. pTyr was
normalized against the immunoprecipitated Lpd. The pTyr signal from Rabbit IgG control lanes was subtracted from the pTyr signal from the
immunoprecipitated Lpd lanes. n= 3, data are represented as mean± s.e.m. One-way ANOVA; Dunnett's; ***P⩽ 0.001, ****P⩽ 0.0001, NS, not
signiﬁcant. (d) HEK293FT cells were transfected with GFP-Lpd, Myc-tagged components of the Scar/WAVE complex and either Src-WT (wild
type) or Src-KI (kinase inactive). Immunoprecipitation was performed from cell lysates using Lpd-speciﬁc antibody or rabbit IgG as a control
followed by western blotting with anti-GFP, anti-Myc and anti-phosphotyrosine (pTyr) antibodies. (e) Quantiﬁed band intensities of
chemiluminescence blots (d) of GFP-Lpd and Myc-tagged components of the Scar/WAVE complex imaged with a CCD camera. Individual Scar/
WAVE components were normalized against the immunoprecipitated Lpd. n= 4, data are represented as mean± s.e.m. One-way ANOVA;
Dunnett's; *P⩽ 0.05, **P⩽ 0.01. (f) HEK293FT cells were transfected with GFP-Lpd, Myc-tagged components of the Scar/WAVE complex and
either GFP-c-Abl or GFP. Immunoprecipitation was performed from cell lysates using Lpd-speciﬁc antibody or rabbit IgG as a control followed
by western blotting with anti-GFP, anti-Myc and anti-phosphotyrosine (pTyr) antibodies. (g) Quantiﬁed band intensities of chemiluminescence
blots (f) of GFP-Lpd and Myc-tagged components of the Scar/WAVE complex imaged with a CCD camera. Individual Scar/WAVE components
were normalized against the immunoprecipitated Lpd. n= 4, data are represented as mean± s.e.m. One-way ANOVA; Dunnett's; **P⩽ 0.01,
***P⩽ 0.001.
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motility was quantiﬁed manually. A cell was scored as motile if the
translocation of the cell body was visible over the course of a 30-min video
within a visual ﬁeld that is deﬁned in three dimensions as 50 μm by
512×512 pixels. Protrusion was deﬁned as tumors cells showing a dynamic
lamellipodia-like morphology. A protrusion was deﬁned to be at least 5 μm
long, but less than half the length of the cell. Directionality was calculated as
described.58
Statistics
Statistical analysis performed by ANOVA with appropriate post hoc tests
(see ﬁgure legends), or Student’s t-test using Prism 5 (GraphPAD Software).
P-values o0.05 considered as signiﬁcant.
Clinical data sets analysis
Oncomine (www.oncomine.org) used for Lpd mRNA expression from
microarray data.21 Statistical survival analysis (Kaplan–Meier plots) was done
with ROCK (http://www.rock.icr.ac.uk). Expression value of Lpd was upper
quartile (25% against rest) for the NKI29524 and Loi22 data sets or upper
tertile (33% against rest) for the Miller23 data set. The log-rank P-value was
used for statistical signiﬁcance.
Tissue microarrays
TMAs were performed with 0.6 mm2 cores of formalin-ﬁxed, parafﬁn-
embedded invasive breast tumor samples (312 consecutive patients) with
clinicopathological data (King’s Health Partners Cancer Biobank, London,
UK). Automated immunohistochemistry (VENTANA Discovery UTLRA)
of 3 μm TMA sections was performed, deparafﬁnized (EZ prep; Ventana
Medical) (30 min, 72 °C), antigen retrieval in automated slide stainer
(ULTRA CC2 solution, Ventana Medical) (68 min, 91 °C). Afﬁnity puriﬁed
polyclonal rabbit Lpd antibody in PBS (1:250) (32 min, room temperature)
was used. Slides counterstained with hematoxylin II and bluing reagent
(Ventana Medical) (4 min each), dehydrated: 1 × 70% IMS, 1 min, 2 × 100%
IMS, 1.5 min, 3 × xylene, 1 min, mounted (Eukitt) and imaged (Leica
microscope, × 40).
Intensity of Lpd in cytoplasm and membrane assessed on TMAs
using weighted histoscore (H-Score) method: intensity in majority of cells
assessed as negative and weak (1), or moderate and strong (2), then
multiplied by the percentage of cells within this category. The weighted
histoscore: 0–200 divided into thirtiles: Cytoplasma: histoscore 1 (0–88.75),
histoscore 2 (88.75–170) and histoscore 3 (170–200); Membrane:
histoscore 1 (0–25), histoscore 2 (25–95) and histoscore 3 (95–200). TMAs
were assessed by two independent observers (UP and CG). Intensity scores
that varied by more than a factor of one or a proportion by more than 20%
were jointly reassessed and consensus reached. For all other cases, the
mean score was used. Disease-speciﬁc survival curves generated using the
Kaplan–Meier method. The log-rank test was used to compare statistically
signiﬁcant differences between subgroups. Univariate and multivariate
analyses Cox proportional hazards regression models used to evaluate
overall and breast cancer-speciﬁc death by histoscore of Lpd intensity in
cytoplasm and at membrane. All analyses were performed using Statistical
Analysis Systems (SAS) 9.4 (SAS Institute, Cary, NC, USA).
Study approval
The study approval was obtained for TMA from NHS Research Ethics
Committee, King’s Health Partners Cancer Biobank, London, UK. Mice: all
animal experiments and husbandry were approved by MIT’s Department of
Comparative Medicine and Committee on Animal Care. The study approval
was obtained for Zebraﬁsh from Northern Stockholm Experimental Animal
Ethical Committee.
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